Steven Weitman appointed as MIDD member

The MIDD has welcomed Steven Weitman as new member. Dr. Weitman was the AT&T Distinguished Chair for Drug Development at the University of Texas Health Science Center at San Antonio and is currently enjoying his retirement in Wisconsin. He obtained… Read More

MIDD Symposium 2023

The MIDD Symposium will bring together UWM faculty members, students and followers supporting interdisciplinary research in Drug Discovery. This is a in-person and online event. This year we invited speakers from our industry partners and startup companies located at UWM…. Read More

Taufeeque Ali appointed MIDD research assistant for Spring 2023

Graduate Student Taufeeque Ali has been selected by MIDD members based on scientific merit and potential to accelerate the development of Novel Combination Strategies for Tumor-Selective Activation of ROS-Activated DNA Cross-Linking Agents. Together with undergraduate students Dhivyashree Senthil Murugan, Alexis… Read More

Estrigenix has been awarded phase 1 SBIR grant

We are thrilled to share that Estrigenix Therapeutics has been awarded a phase 1 SBIR grant from the National Institute of Health. The one-year grant provides funds to support pre-clinical studies on one of Estrigenix’s lead compounds to reduce women’s… Read More

Dr. Avik Roy (Simmaron) receives prestigious Ramsay Award.

The Ramsay Research Grant, awarded by Solve M.E. Foundation, supports research to understand the underlying causes of ME/CFS and Long Covid. Dr. Avik Roy has received this Award in 2022. He is part of Simmaron’s new research team, which moved… Read More

Pantherics Incorporated Receives SBIR Funding from the NIH to Advance New Drug Development

Pantherics Incorporated, a UWM startup company received a $255,841 Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute, to advance development of a fundamentally novel anti-inflammatory drug, with… Read More

Drs. Frick and Arnold receive “Bradley Catalyst” grant funding

The UWM Research Foundation has awarded “Bradley Catalyst” funding to Prof. Frick to evaluate new lead compound EGX854, which has demonstrated greater selectivity and 4-fold better potency. EGX854 has also shown potential for better brain penetration. Dr. Frick will evaluate… Read More

MIDD conducts pre-clinical studies with Estrigenix’s lead for hot flashes and dementia

After a successful fund raising campaign, local startup company Estrigenix has engaged the MIDD to conduct pre-clinical characterization of their lead compounds. Estrigenix Therapeutics was formed in 2018 as a spin out from a collaboration research of three Milwaukee area… Read More

Function Therapeutics, Inc. moves to UWM

Milwaukee startup company Function Therapeutics moves to the Chemistry Department at UWM to conduct their R&D. The company is led by Dr. Chris Dockendorff (formerly Marquette Chemistry faculty), and is focused on the medicinal chemistry of a new class of… Read More

Two UWM startup companies received Phase II Bridge Funding from the UWM Research Foundation.

The University of Wisconsin Research Foundation’s Bridge Grant Program bolsters efforts to commercialize innovations developed at the UWM and foster development of startup companies that improve the Wisconsin economy. The program leverages a grant from the Wisconsin Economic Development Corporation… Read More